Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 2/20 | 0.49 |
| ▸ | FBP1 | P09467 | 12/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145009 | 1.00 | VCP (0.49) | VCPFBP1MEN1PSMD14KMT2A | |
| SCHEMBL19995519 | 0.87 | VCP (0.58) | VCPFBP1MEN1PSMD14KMT2A | |
| SCHEMBL461165 | 0.87 | MEN1 (0.52) | VCPFBP1MEN1PSMD14KMT2A | |
| SCHEMBL19995518 | 0.87 | VCP (0.58) | VCPFBP1MEN1PSMD14KMT2A | |
| SCHEMBL461799 | 0.87 | MEN1 (0.52) | VCPFBP1MEN1PSMD14KMT2A | |
| SCHEMBL20177945 | 0.84 | HSP90AA1 (0.46) | VCPFBP1MEN1PSMD14KMT2A | |
| SCHEMBL18590415 | 0.84 | MEN1 (0.54) | VCPFBP1MEN1PSMD14KMT2A | |
| SCHEMBL5924310 | 0.82 | HSP90AA1 (0.47) | VCPFBP1MEN1PSMD14KMT2A | |
| SCHEMBL5924313 | 0.82 | HSP90AA1 (0.47) | VCPFBP1MEN1PSMD14KMT2A | |
| SCHEMBL612345 | 0.80 | FBP1 (0.56) | VCPFBP1MEN1PSMD14KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2019-11-07 | — | — | US | disclosed |
| EP-3515433-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2019-07-31 | — | — | EP | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| US-20170313715-A1 | SIX-MEMBERED RING BENZO DERIVATIVES AS DPP-4 INHIBITOR AND USE THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313715-A1 | SIX-MEMBERED RING BENZO DERIVATIVES AS DPP-4 INHIBITOR AND USE THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3214079-A1 | SIX-MEMBERED RING BENZO DERIVATIVES AS DPP-4 INHIBITOR AND USE THEREOF | East China University Of Science And Technology (CN) | 2017-09-06 | — | — | EP | disclosed |
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| US-7834012-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| EP-1919854-A2 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007027651-A2 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20060264433-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | VCP 3927/4885FBP1 2246/4885MEN1 2536/4885 |
| US-20060264433-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | VCP 2226/4885FBP1 268/4885MEN1 3363/4885 |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | VCP 1990/4885FBP1 295/4885MEN1 3172/4885 |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | VCP 4063/4885FBP1 1962/4885MEN1 2929/4885 |
| US-20170313715-A1 | SIX-MEMBERED RING BENZO DERIVATIVES AS DPP-4 INHIBITOR AND USE THEREOF | DPP4, DPP7, DPP3 | VCP 1763/4885FBP1 149/4885MEN1 2963/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | VCP 4081/4885FBP1 2345/4885MEN1 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.